Home The Word Brain My Amedeo FAQ Privacy About


Amedeo Chinese

For Medical Students & Physicians

A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever.

Download the free PDF: Amedeo Chinese PDF

  Neoplasms of the CNS

  Free Subscription


25.05.2026

1 Acta Neuropathol
2 BMC Cancer
2 BMC Neurol
2 Br J Cancer
1 Cancer
1 Cancer Res
2 Childs Nerv Syst
1 Clin Cancer Res
1 Int J Radiat Oncol Biol Phys
1 J Neurochem
14 J Neurooncol
1 J Neurosurg
12 Neuro Oncol
3 Neuroradiology
3 Neurosurgery
3 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Acta Neuropathol

  1. GOVAERTS CW, van Dijk JMC, van der Hoorn A, Kruyt FAE, et al
    Future directions in the treatment of brain metastases: evaluating the role of cellular players in the tumour microenvironment.
    Acta Neuropathol. 2026;151:58.
    PubMed         Abstract available


    BMC Cancer

  2. QI F, Chen Y, Han Y, Jiang P, et al
    EGFR-TKI monotherapy versus combination therapy as first-line treatment for EGFR-mutant NSCLC with brain metastases: a real-world comparison analysis.
    BMC Cancer. 2026 May 20. doi: 10.1186/s12885-026-16193.
    PubMed         Abstract available

  3. LIU D, Liu Y, Ci Y, Wang C, et al
    Efficacy and safety of targeted therapies for glioblastoma: a systematic review and network meta-analysis.
    BMC Cancer. 2026 May 18. doi: 10.1186/s12885-026-16190.
    PubMed         Abstract available


    BMC Neurol

  4. KO K, Park YJ, Hwang K, Park YH, et al
    Reversibility of cognitive and psychiatric impairments following surgical resection of frontotemporal meningiomas: a predictive factor analysis.
    BMC Neurol. 2026 May 20. doi: 10.1186/s12883-026-04972.
    PubMed         Abstract available

  5. DA R, Wang M, Jiang H, Wang W, et al
    BRAF-amplified glioblastoma patients have a worse prognosis than those with BRAF mutation and are associated with amplification of MET, RHEB and CUL1.
    BMC Neurol. 2026 May 18. doi: 10.1186/s12883-026-04982.
    PubMed         Abstract available


    Br J Cancer

  6. SKRIBEK M, Livanou ME, Vathiotis I, Strandman V, et al
    The brain-lung immunotherapy prognostic (BLIP) Score: a novel robust tool for prognostication in non-small cell lung cancer patients with brain metastases.
    Br J Cancer. 2026 May 20. doi: 10.1038/s41416-026-03470.
    PubMed         Abstract available

  7. WANG X, Xie Y, Hu J, Liu N, et al
    Furmonertinib combined with bevacizumab in EGFR-TKI-resistant leptomeningeal metastasis: analysis of the CSF ctDNA molecular response and survival outcomes.
    Br J Cancer. 2026;134:1614-1623.
    PubMed         Abstract available


    Cancer

  8. KESSEL AC, Kim H, Brown PD, Lehrer EJ, et al
    Cost-effectiveness of vorasidenib in treatment of isocitrate dehydrogenase-mutated low-grade glioma.
    Cancer. 2026;132:e70463.
    PubMed         Abstract available


    Cancer Res

  9. CLUBB JD, Shih RM, Gao TA, Shafer A, et al
    Armored chimeric antigen receptor T-cell therapy targets antigen-heterogeneous glioma.
    Cancer Res. 2026 May 20. doi: 10.1158/0008-5472.CAN-26-1515.
    PubMed         Abstract available


    Childs Nerv Syst

  10. EROL A, Karagoz C, Ay LA, Cinar C, et al
    Delayed presentation of a pediatric giant traumatic pseudoaneurysm mimicking a brain tumor: a case report.
    Childs Nerv Syst. 2026;42:225.
    PubMed         Abstract available

  11. VISOCCHI E, Camelia M, Spezzani C, Noris A, et al
    Primary intraosseous meningioma in a child: an unusual case report and literature review.
    Childs Nerv Syst. 2026;42:223.
    PubMed         Abstract available


    Clin Cancer Res

  12. EHRET F, Horick NK, Yeap BY, Curry WT, et al
    Dose Escalation With Intensity-Modulated Proton Therapy for Patients with High-Risk Meningiomas - Results From a Phase 1 Trial.
    Clin Cancer Res. 2026 May 18. doi: 10.1158/1078-0432.CCR-25-3856.
    PubMed         Abstract available


    Int J Radiat Oncol Biol Phys

  13. PERLOW HK, Hennings S, Bradshaw J, Reddy S, et al
    Preoperative Versus Postoperative Fractionated Stereotactic Radiation Therapy: A Single-Institution Analysis of 534 Resected Metastases.
    Int J Radiat Oncol Biol Phys. 2026;125:502-510.
    PubMed         Abstract available


    J Neurochem

  14. GUERRIERO C, De Nuccio C, Petrone M, Rinaldi T, et al
    Dualsteric Agonist for M2 Muscarinic Receptor Causes Oxidative Stress and Mitochondrial Alteration in Human Glioblastoma Cancer Stem Cells.
    J Neurochem. 2026;170:e70454.
    PubMed         Abstract available


    J Neurooncol

  15. WONG DKK, Pu JKS, Li LF, Hui VKH, et al
    Health-related quality-of-life of WHO grade 4 astrocytoma patients receiving alternating electrical field therapy: a prospective real-world multi-centre study.
    J Neurooncol. 2026;178:16.
    PubMed         Abstract available

  16. PALIT SR, Shinya Y, Celda MP, Karsy M, et al
    Risk factors for postoperative cerebrospinal fluid leak following endoscopic transsphenoidal surgery for craniopharyngioma: a multicenter cohort study with a contemporary surgeon practice survey.
    J Neurooncol. 2026;178:13.
    PubMed         Abstract available

  17. SKARIN N, Hallbeck M, Werlenius K, Rohan Z, et al
    MGMT promoter methylation status for glioblastoma: defining the clinically relevant cut-off value for pyrosequencing.
    J Neurooncol. 2026;178:12.
    PubMed         Abstract available

  18. JIA JL, Alshamsan B, Andronic C, Fazzari F, et al
    Treatment patterns and outcomes in high-risk WHO grade 2 diffuse glioma: a multicentre retrospective cohort study.
    J Neurooncol. 2026;178:10.
    PubMed         Abstract available

  19. ZEYEN T, Decker A, Krause I, Kroh F, et al
    APTw CEST MRI in therapy-naive IDH-wildtype glioblastoma: insights into tumor heterogeneity and molecular subtypes.
    J Neurooncol. 2026;178:9.
    PubMed         Abstract available

  20. VENTURA E, Alanesi A, Achterling M, Fistouris P, et al
    Impact of postoperative tumor volume and relative volume reduction to predict meningioma recurrence - a retrospective analysis.
    J Neurooncol. 2026;178:7.
    PubMed         Abstract available

  21. SHIDOH-KAZUKI R, Fujikawa Y, Kawabata S, Tsujino K, et al
    Boron neutron capture therapy prolongs survival in a rat model of multifocal brain metastases.
    J Neurooncol. 2026;178:8.
    PubMed         Abstract available

  22. BINDAL K, Dono A, Tandon N, Esquenazi Y, et al
    Laser interstitial thermal therapy versus stereotactic radiosurgery for first-time treatment of recurrent glioblastoma: a retrospective single-center study.
    J Neurooncol. 2026;178:6.
    PubMed         Abstract available

  23. WIERZBICKI M, Bowden SG, Robert SM, Wang SY, et al
    Care pathways for asymptomatic brain metastases: comparison of healthcare utilization, costs, and outcomes in outpatient versus acute settings.
    J Neurooncol. 2026;178:5.
    PubMed         Abstract available

  24. IZHAR M, Hori YS, Kattaa AH, Harary PM, et al
    Outcome of CyberKnife stereotactic radiosurgery for the brain metastases in patients with Li Fraumeni syndrome.
    J Neurooncol. 2026;178:4.
    PubMed         Abstract available

  25. LEVIN-CARRION Y, Bhasin J, Titkov K, Anne S, et al
    Should checkpoint inhibitors be reserved for biomarker-selected pediatric brain tumors?
    J Neurooncol. 2026;178:2.
    PubMed         Abstract available

  26. PALUMBO C, De Schlichting E, Le Lann F, Leboucher A, et al
    Timing of adjuvant chemoradiotherapy after resection and survival in glioblastoma: a single-centre cohort analysis.
    J Neurooncol. 2026;177:150.
    PubMed         Abstract available

  27. BECHT K, Lindsay ME, Soulos PR, Singh C, et al
    Disparities in stereotactic radiosurgery receipt in patients with brain metastases from non-small cell lung cancer.
    J Neurooncol. 2026;177:151.
    PubMed         Abstract available

  28. ARJUNA S, Pirhoushiaran M, Bueno A, Sanchez-Espitia A, et al
    CSF ctDNA analysis guides molecular reclassification of diffuse glioma patients.
    J Neurooncol. 2026;178:14.
    PubMed         Abstract available


    J Neurosurg

  29. O'LEARY S, Fu AY, Rogers VA, Perdikis B, et al
    Optimal timing of PD-1 inhibitor immunotherapy administration to stereotactic radiosurgery in malignant gliomas: a propensity score-matched multi-institutional cohort study.
    J Neurosurg. 2026 May 15:1-12. doi: 10.3171/2025.12.JNS252327.
    PubMed         Abstract available


    Neuro Oncol

  30. SMITH AA, Onar-Thomas A, Lensing S, Dalton J, et al
    Phase 3 randomized trial of postirradiation chemotherapy in patients with newly diagnosed ependymoma: A report from the Children's Oncology Group.
    Neuro Oncol. 2026;28:1286-1297.
    PubMed         Abstract available

  31. SCHAFF LR, Pentsova E, Malani R, Stone J, et al
    Ibrutinib in combination with rituximab, methotrexate, vincristine, and procarbazine for newly diagnosed primary CNS lymphoma.
    Neuro Oncol. 2026;28:1277-1285.
    PubMed         Abstract available

  32. TOS SM, Shaaban A, Hamdan D, Mantziaris G, et al
    Single-fraction stereotactic radiosurgery for residual, recurrent, or metastatic intracranial solitary fibrous tumors: An IRRF study toward management guidance.
    Neuro Oncol. 2026;28:1251-1265.
    PubMed         Abstract available

  33. GHASEMI DR, Obrecht-Sturm D, Wallgren KM, Schuhmann MU, et al
    A brief history of ependymoma.
    Neuro Oncol. 2026;28:1085-1100.
    PubMed         Abstract available

  34. RAJAN A, Castro FR, de Godoy LL, Hanaoka M, et al
    Imaging biomarkers for detecting IDH mutations and monitoring response to novel targeted therapies: Current insights and future perspectives.
    Neuro Oncol. 2026;28:1101-1116.
    PubMed         Abstract available

  35. YEFET LS, Landry AP, Rogers CL, Wang JZ, et al
    Modern Molecular Profiling Recontextualizes the NRG/RTOG 0539 Trial and Reveals Hidden High-Risk and Radiotherapy Resistant Meningiomas.
    Neuro Oncol. 2026 May 15:noag081. doi: 10.1093.
    PubMed         Abstract available

  36. LIU S, Bai Z, Qiao Y, Ge Y, et al
    LDHA-mediated CREB1 Lactylation Promotes Breast Cancer Brain Metastasis by Transcriptionally Activating Cytoskeletal Remodeling.
    Neuro Oncol. 2026 May 21:noag114. doi: 10.1093.
    PubMed         Abstract available

  37. BRAMAN BC, Cady MA, Merz-Herrala AA, Witztum A, et al
    Epidemiological and clinical data link depot medroxyprogesterone acetate to meningioma.
    Neuro Oncol. 2026 May 21:noag115. doi: 10.1093.
    PubMed         Abstract available


  38. Corrigendum to: Immune landscape of isocitrate dehydrogenase-stratified primary and recurrent human gliomas.
    Neuro Oncol. 2026;28:e18.
    PubMed        

  39. KOTCH C, Perreault S, Power P, Adams DJ, et al
    Tempered Optimism: Advances in the Precision Medicine Era for Pediatric Low-Grade Glioma.
    Neuro Oncol. 2026 May 19:noag111. doi: 10.1093.
    PubMed         Abstract available

  40. BRAT DJ, Aldape K, French PJ, Louis DN, et al
    cIMPACT-NOW update 12: Refining Pathology-based Risk Stratification and Grading for IDH-mutant Gliomas.
    Neuro Oncol. 2026 May 18:noag108. doi: 10.1093.
    PubMed         Abstract available

  41. HIRUNPATTARASILP C, Newton HB
    The emerging roles of cerebral pericytes in brain metastasis.
    Neuro Oncol. 2026 May 19:noag110. doi: 10.1093.
    PubMed         Abstract available


    Neuroradiology

  42. HE S, Li Z, Li J, Lin R, et al
    Multimodal integration of radiomics, pathomics, and clinical data enhances grading of adult diffuse gliomas using machine learning.
    Neuroradiology. 2026 May 19. doi: 10.1007/s00234-026-04015.
    PubMed         Abstract available

  43. PRASAD S, Saini J, Dubey NK, Tsai LW, et al
    Beyond gross total resection (GTR): Deep peritumoral radiomics for predicting overall survival (OS) and O6-methylguanine-DNA-methyltransferase promoter methylation (MGMTpm) status in glioblastoma multiforme.
    Neuroradiology. 2026 May 18. doi: 10.1007/s00234-026-04016.
    PubMed         Abstract available

  44. DEMIREL E, Dilek O
    T2-FLAIR digital subtraction radiomics versus neuroradiologist visual assessment for differentiating IDH-mutant astrocytomas from other non-enhancing low-grade gliomas: An externally validated machine learning study.
    Neuroradiology. 2026 May 15. doi: 10.1007/s00234-026-04025.
    PubMed         Abstract available


    Neurosurgery

  45. LOZOUET M, Maquet C, Horion J, Garrido E, et al
    Complications of Cerebral Venous Thrombosis After Cerebellopontine Angle Tumor Resection: A STROBE Retrospective Observational Cohort Study.
    Neurosurgery. 2025 Oct 7. doi: 10.1227/neu.0000000000003761.
    PubMed         Abstract available

  46. EVANS LR, Zhao YC, Castle-Kirszbaum M, Kam J, et al
    Improving the Assessment of Visual Outcomes After Resection of Tuberculum Sellae Meningiomas.
    Neurosurgery. 2026 May 19. doi: 10.1227/neu.0000000000004094.
    PubMed         Abstract available

  47. PICHARDO-ROJAS PS, Pichardo-Rojas D, Ochoa-Hernandez D, Marin-Castaneda LA, et al
    Prognostic Validation of the RANO-Resect Classification and Non-Contrast-Enhancing Tumor Resection: A Meta-Science Study in Glioblastoma Surgery.
    Neurosurgery. 2026 May 19. doi: 10.1227/neu.0000000000004085.
    PubMed         Abstract available


    PLoS One

  48. DEMIRAG AD, Aksoy RA, Akman G, Kaya V, et al
    Comprehensive quantum chemical analysis, vibrational spectroscopy, molecular docking, ADMET, and in vitro validation studies of hydroxychloroquine-MRGPRX2 complex in IDH-wildtype glioblastoma.
    PLoS One. 2026;21:e0347956.
    PubMed         Abstract available

  49. KIRUBAKARAN M, Mohan J
    A novel hybrid framework integrating GA-driven 3D ResUNetGAN for MRI brain tumor segmentation.
    PLoS One. 2026;21:e0349451.
    PubMed         Abstract available

  50. BLOMBERG L, Raba L, Bengzon J, Osther K, et al
    Overexpression of key complement regulators in glioblastoma.
    PLoS One. 2026;21:e0349101.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Neoplasms of the CNS is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum